Article Details
Retrieved on: 2021-10-04 19:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In 2018, AstraZeneca paid $10 million up front to garner exclusive rights to Compugen's monospecific antibodies that bind to TIGIT, including COM902, with the ...
Article found on: www.precisiononcologynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here